drugset / Trial / NCT02239835

Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients

NCT02239835

Phase 2 Terminated 79 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

Objectives of the study were to evaluate the efficacy and safety of two different doses of tipranavir (TPV) in combination with ritonavir (TPV/r) compared with a standard dual PI combination of saquinavir (SQV) and ritonavir (RTV) and to evaluate the dose response of two different doses of TPV in combination with RTV for efficacy and safety.

Timeline

Start
1999-12
Primary completion
2001-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ritonavir Other / unclassified
Comparator Saquinavir Small molecule
Subject Tipranavir Small molecule